NewKerala.com

Key Points

A groundbreaking study in Zimbabwe has discovered that a common, affordable antibiotic could significantly reduce preterm births among HIV-positive pregnant women. Researchers found that daily trimethoprim-sulfamethoxazole dramatically lowered premature birth rates, with only 6.9% of women on the antibiotic experiencing preterm births compared to 11.5% in the placebo group. The research, published in the New England Journal of Medicine, offers a promising new strategy to combat infant mortality, particularly in regions with high HIV prevalence. These findings could potentially transform maternal and child healthcare approaches in resource-limited settings.

Key Points: HIV Pregnancy Antibiotics Cut Preterm Birth Risks Significantly

  • Large Zimbabwe study explores antibiotic impact on HIV-positive pregnancies
  • Daily trimethoprim-sulfamethoxazole reduced preterm birth rates by 40%
  • Research published in New England Journal of Medicine
  • Potential low-cost intervention for maternal and infant health
3 min read

Antibiotics during pregnancy may reduce preterm births in women with HIV: Study

Zimbabwe study reveals trimethoprim-sulfamethoxazole may reduce preterm births among HIV-positive pregnant women, offering new hope for infant survival.

"We desperately need new strategies to prevent preterm births - Andrew Prendergast, Queen Mary University of London"

New Delhi, June 6

A daily dose of a commonly used, safe, and inexpensive antibiotic may help reduce preterm births (born at 37 weeks’ gestation or before), in women with HIV, according to a study of almost 1,000 pregnant women in Zimbabwe.

An international group of researchers, from the UK and Zimbabwe, found that women living with HIV who took the antibiotic trimethoprim–sulfamethoxazole during their pregnancy had larger babies who were less likely to be preterm.

Trimethoprim–sulfamethoxazole is a broad-spectrum antimicrobial agent with anti-inflammatory properties that are widely used in sub-Saharan Africa.

The study showed that for babies born to a small group of 131 women with HIV, the reduction in premature births was especially marked, with only 2 per cent of births in the trimethoprim–sulfamethoxazole group preterm, as compared with 14 per cent in the placebo group.

“Our findings suggest that a low-cost, daily antibiotic, in a setting where infections like HIV are common, might reduce the risk of preterm births. We desperately need new strategies to prevent preterm births, which are the leading cause of under-5 child mortality,” said Andrew Prendergast, Professor of Paediatric Infection and Immunology at Queen Mary University of London.

“If we can confirm in other trials that trimethoprim-sulfamethoxazole reduces the risk of babies being born too soon, it would be a promising new approach to help newborns survive and thrive,” he added.

One in four live-born infants worldwide is preterm, is small for gestational age, or has a low birth weight.

The mortality rate for these small and vulnerable newborns is high, with prematurity now the leading cause of death among children younger than 5 years of age.

Maternal infections and inflammation during pregnancy are linked to adverse birth outcomes, particularly for babies born to mothers living with HIV, who have a greater risk of being born too small or too soon.

The randomised controlled trial included 993 pregnant women from three antenatal clinics in central Zimbabwe, and gave them either 960 mg of the drug or a placebo daily.

The study, published in the New England Journal of Medicine, found that although birth weight did not differ significantly between the two groups, the trimethoprim–sulfamethoxazole group showed a 40 per cent reduction in the proportion of preterm births, compared to the placebo group.

Overall, 6.9 per cent of mothers receiving the drug had babies born preterm, compared to 11.5 per cent of mothers receiving the placebo, and no women receiving antibiotics had babies born before 28 weeks.

- IANS

Share this article:

Reader Comments

P
Priya K.
This is such promising research! In India where HIV awareness is still growing, affordable interventions like this could save so many lives. Hope our medical community takes note and conducts similar studies here. 🙏
R
Rahul S.
Interesting findings but we must be careful. Antibiotic resistance is already a major problem in India. Shouldn't we focus more on preventing HIV transmission first rather than relying on antibiotics during pregnancy?
A
Ananya M.
As a medical student, I find this fascinating! The anti-inflammatory properties of trimethoprim-sulfamethoxazole might be the key here. Would love to see if similar benefits exist for non-HIV pregnant women with infections.
V
Vikram J.
Good research but implementation will be challenging in rural India where many HIV+ women don't even get proper antenatal care. We need better healthcare infrastructure first.
S
Sunita R.
Every life saved matters! If this simple treatment can prevent premature births, our government should consider including it in the national HIV program. So many families could benefit from this.
K
Karthik N.
The study size seems quite small (only 131 women with HIV). Before we get too excited, we need larger trials to confirm these results. But definitely a step in the right direction!

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50